Dr. Nielsen Discusses Using a Ki67 Assay in Breast Cancer

Torsten O. Nielsen, MD, PhD, FRCPC
Published Online: Tuesday, August 13, 2013
Torsten O. Nielsen, MD, PhD, FRCPC, professor, pathology, University of British Columbia, on using a Ki67 assay for patients with breast cancer.

A Ki67 assay is cheap, easy, convenient, and gives a physician important information about a patient. Ki67 is a convenient immunohistochemical tool for measuring proliferation, which is a critical factor in breast cancer, though there are some issues with analytical validity. If a physician wants to administer a Ki67 test, he/she must internally validate the test and interpretation, demonstrating analytical validity for the clinical indication in question.

In order to adopt a cut point, one must carefully benchmark an interpretation of Ki67 against existing papers and methods in order to make safe clinical decisions, Nielsen says. Otherwise, there remains a chance of significant bias in an assessment of Ki67, resulting in potentially wrong clinical decisions.

Online CME Activities
Free CME from PER
Highlights From the 13th Annual International Congress on the Future of Breast Cancer®
Pancreatic Cancer: Novel and Emerging Approaches to Early Detection and Treatment
Oncology Best Practice: Challenges in Treating Chronic Lymphocytic Leukemia – The Older Patient and Comorbid Conditions
OncoLogue: Breast Cancer Cases
More Reading
Publications
$auto_registration$